Moxetumomab pasudotox-tdfk in heavily pretreated patients with relapsed/refractory hairy cell leukemia: long-term follow-up from the pivotal Phase 3 trial Robert J. Kreitman et al, 2019 Date sam, 12/07/2019 - 10:33
